TRT and the Prostate: The Definitive Guide

What does testosterone do to the prostate, and what is PSA?

The prostate is a small, walnut-sized gland under the bladder that makes part of the fluid in semen. It depends on male hormones, and testosterone drives the growth of prostate cancer once it has spread, which is why testosterone therapy and the prostate are watched together. [13], [1]

PSA (prostate-specific antigen) is a protein the prostate makes, measured with a blood test. It is specific to the prostate but not to cancer: an enlarged prostate, inflammation, infection, recent ejaculation, long cycling and some procedures can all raise it. A single high result is a reason to look further, not a diagnosis. [17], [13]

PSA production depends on testosterone, so men with low testosterone tend to have lower PSA, and treatment usually nudges it up a little, mostly in the first year. [17], [18], [1]

Two other prostate problems come up on TRT:

• BPH (benign prostatic hyperplasia) is an enlarged prostate that is not cancer. It can cause lower urinary tract symptoms such as peeing more often, a sudden urge to go and getting up at night to urinate. Doctors score these with a short questionnaire, the IPSS, and TRT guidelines treat a score above 19 as severe. [13], [3]
• Prostate cancer usually grows slowly; once it has spread, a standard treatment lowers testosterone (androgen deprivation therapy), which is where the old belief that testosterone "feeds" every prostate cancer came from. [1], [19]

TRT and the prostate: the key numbers

Two sets of numbers matter: the checks before treatment starts, and the change in PSA during treatment that leads to a urology referral. The tables show what each major clinical guideline says, checked in September 2026. PSA is written in ng/mL; UK, Canadian and Australian labs write the same number in µg/L.

Before starting: prostate checks by guideline

[9], [2], [3], [4], [10], [5], [20], [21], [22], [23]

Most bodies want a PSA, often with a DRE, before treatment in men over 40, and treat an unevaluated PSA above 4 ng/mL (above 3 ng/mL at high risk) as a reason to see a urologist first. The Endocrine Society's higher-risk factors include a father or brother with prostate cancer and African American race. [2]

On treatment: when a PSA change leads to referral

[2], [3], [4], [5], [10], [20], [9], [24], [25]

The Endocrine Society, the VA and the EAA refer a man for a rise of more than 1.4 ng/mL in the first year, or a PSA above 4 ng/mL. The BSSM uses a rise of more than 1.4 ng/mL in any year, or more than 0.4 ng/mL a year over 2 years. The Endocrine Society asks for both results to be confirmed on a repeat test, and the EAA for the result above 4 ng/mL. The EAU, the CUA and the AUA fall back on general prostate cancer guidance. [2], [3], [4], [5], [10], [20], [9]

Doserly

When a PSA result on TRT leads to a urology referral

The two triggers most guidelines use, and who uses which.

1. 1. A rise of more than 1.4 ng/mLin the first year, compared with your own starting PSA (the BSSM: in any year).
2. 2. A PSA above 4 ng/mLat any time during treatment (4 ng/mL is 4 µg/L).

Endocrine Society (2018)

A confirmed rise of more than 1.4 ng/mL in the first 12 months; a confirmed PSA above 4 ng/mL; an abnormal rectal exam.

BSSM (UK, 2023)

A rise of more than 1.4 ng/mL in any 1-year period, or more than 0.4 ng/mL a year over more than 2 years. The 6-month PSA is the new baseline.

VA (US, January 2026)

A rise of more than 1.4 ng/mL within 12 months, or a PSA above 4 ng/mL at any time.

EAA (Europe, 2020)

A rise of more than 1.4 ng/mL within 12 months, or a confirmed PSA above 4 ng/mL.

EAU (Europe, 2026)

No number: a “significant rise” in PSA or its speed leads to further tests.

CUA and AUA (Canada, 2021; US, 2018)

No testosterone-specific number: general prostate cancer screening guidance.

The Endocrine Society confirms both on a repeat test; the EAA confirms a result above 4 ng/mL. On finasteride or dutasteride PSA reads about half; TRAVERSE halved its triggers for these men (0.7 and 2.0 ng/mL).

Where does the 1.4 ng/mL figure come from?

From normal test-to-test wobble. The Endocrine Society explains that 1.4 ng/mL is the 90% confidence limit for the change between two PSA tests taken 3 to 6 months apart in men with BPH, so a bigger rise is more than ordinary test-to-test variation. In the Testosterone Trials, rises of more than 1.4 ng/mL happened in 2.4% of men on testosterone at 3 months and 4.7% at 12 months, against 1.6% and 0.6% on placebo. [2]

Why do guidelines disagree?

Mostly because prostate cancer screening itself is disputed, and each testosterone guideline borrows its own country's screening rules:

• Screening by age. The US Preventive Services Task Force leaves screening at 55 to 69 to individual choice and advises against it at 70 and older (an update is in progress). The AUA's early-detection guideline suggests a first PSA at 45 to 50, then every 2 to 4 years from 50 to 69. The EAU starts at 50, earlier with a family history, African descent or a BRCA2 gene change. The NHS offers no routine screening unless a man carries a faulty BRCA2 gene. Checked September 2026. [26], [27], [28], [17], [13]
• The rectal exam. The EAU wants a DRE at the start and at least yearly; the BSSM advises one at the start, then yearly PSA; the UK Society for Endocrinology does not recommend mandatory screening at all. [10], [3], [22]

How do the units and medicines change the numbers?

PSA in ng/mL and µg/L is the same number: 4 ng/mL is 4 µg/L. Finasteride and dutasteride, taken for an enlarged prostate or hair loss, lower PSA by about half. So their labels say to double a result before comparing it with normal ranges (after 6 months on finasteride 5 mg, or 3 months on dutasteride). That is why TRAVERSE, which otherwise used the 1.4 and 4.0 ng/mL triggers, halved them for men on these medicines. [1], [14], [29]

For testosterone itself, the unit converter switches between ng/dL and nmol/L, and the TRT blood work guide explains when to draw each test.

Why does testosterone affect PSA and the prostate?

Because the prostate runs on male hormones, but seems to need only a modest amount. An enzyme, 5-alpha reductase, turns testosterone into a stronger hormone, DHT (dihydrotestosterone), which drives much of the prostate's growth. The evidence below is mostly from people; the "saturation" idea is a model that fits it, not a proven fact. [14], [30], [19]

• Blocking DHT blocks the growth. In a 12-month trial in older men, testosterone injections (125 mg of enanthate a week, which the authors call higher than usual replacement) enlarged the prostate by 11.4 cm³, and finasteride prevented it completely. [30]
• The saturation model. This hypothesis says the prostate's hormone receptors are nearly full at fairly low testosterone levels, so raising testosterone into the normal range adds little. [19] Human studies fit it:
• In a 6-month randomized trial with prostate biopsies, injections raised blood testosterone from a median of 282 to 640 ng/dL, but testosterone and DHT inside the prostate did not change significantly. [31]
• In a 6-month gel trial of 274 men, PSA rose 0.2 ng/mL in men who started at 250 ng/dL or below and did not change above that. A registry of 451 men on gel found a statistically clear rise only in men who started below 250 ng/dL, with PSA highest after 1 month. The 250 ng/dL cut-off is where these studies split their groups, not a proven threshold. [32], [18]
• Natural testosterone levels. Pooled data from 18 long-term studies found no link between men's own testosterone and later prostate cancer. A pooling of 20 studies found fewer cancers only in the tenth of men with the lowest free testosterone (odds ratio 0.77). [33], [34]
• The genetic counterweight. Mendelian randomization studies use gene variants as a natural experiment. In UK Biobank, each step up in genetically higher bioavailable testosterone went with a 23% higher prostate cancer risk (odds ratio 1.23), and a second study found the same for aggressive cancer. These reflect lifelong exposure, not treatment started later, but the TRAVERSE authors cite them as the reason prostate safety still needs study. [35], [36], [1]

Does low testosterone hide prostate cancer?

It can make PSA less reassuring. In 77 men with low testosterone, a PSA of 4.0 ng/mL or less and a normal rectal exam, biopsies found cancer in 14%. In a later series of 345 men, the figure was 15.1%, rising from 5.6% at a PSA of 1.0 or less to 36.4% at 3.1 to 4.0. Neither series had a comparison group. The EAU notes that low testosterone lowers PSA, one reason guidelines check it before and after treatment starts. [37], [38], [17]

What does the research show?

PSA rises a little on testosterone, trials have not shown more prostate cancer or worse average urinary symptoms, and the long-term answer is still open because the cancer grows over many years. [1], [39], [40]

How much does PSA rise on TRT?

A few tenths of a ng/mL on average, mostly in the first year, with a few men rising much more.

The pattern: a small average rise, bigger in older men and those starting very low, with a few larger rises. There is no single "normal" rise, which is why guidelines use a referral trigger. [32], [41], [2]

Does TRT cause prostate cancer?

Randomized trials have not shown it, but they are short compared with how slowly prostate cancer grows.

TRAVERSE, the largest trial, had an independent committee confirm prostate events over 14,304 person-years in 5,204 men: [1]

• High-grade prostate cancer: 5 of 2,596 men on testosterone (0.19%) and 3 of 2,602 on placebo (0.12%) (hazard ratio 1.62, likely range 0.39 to 6.77, too wide to show a difference). [1]
• Any prostate cancer: 12 men (0.46%) vs 11 (0.42%). [1]
• Referrals and biopsies: 57 men on testosterone (2.2%) and 28 on placebo (1.1%) met the referral rules; 16 of those 85 chose a biopsy. In all, 16 men on testosterone and 14 on placebo had a biopsy. [1]
• Limits: men with a PSA above 3.0 ng/mL or severe urinary symptoms were excluded; it tested only a gel; men used it for 21.7 months on average, and about 61% stopped early. [1], [6], [44]

Doserly

TRAVERSE: prostate events, counted in men

Testosterone gel (2,596 men)Placebo gel (2,602 men)

Numbers are men with the event (percent of the group). Bars run from 0 to 110 men.

High-grade prostate cancer

Testosterone 5 (0.19%) vs placebo 3 (0.12%); hazard ratio 1.62 (95% CI 0.39–6.77), not significant

Any prostate cancer

Testosterone 12 (0.46%) vs placebo 11 (0.42%)

Prostate biopsy

Testosterone 16 vs placebo 14

Acute urinary retention

Testosterone 20 (0.77%) vs placebo 16 (0.61%)

Procedure for BPH

Testosterone 23 (0.89%) vs placebo 12 (0.46%); hazard ratio 1.91 (95% CI 0.95–3.84), not significant

New urinary (LUTS) medicine

Testosterone 101 (3.89%) vs placebo 87 (3.34%)

None of the differences was statistically significant. Men with a PSA above 3.0 ng/mL or severe urinary symptoms were excluded.

Reviews of smaller trials agree. The newest (2026; 41 trials, 11,161 men) found no clear change in prostate cancer (odds ratio 0.88, likely range 0.52 to 1.51) or clinically significant cancer (1.13). Earlier reviews of 11, 22 and 51 studies found no significant effect. A 2005 review found more "prostate events" (odds ratio 1.78), but it counted PSA rises and biopsies together, and none was significant on its own. [39], [45], [46], [47], [48]

Large records studies (cohort studies) follow more men for longer, but show only links:

• Sweden (38,570 men with prostate cancer, 192,838 without): no link overall (odds ratio 1.03); more low-risk cancers found early (1.35), which the authors put down to more testing, and fewer aggressive ones (0.50). [49]
• US Medicare (52,579 men with prostate cancer): no link with high-grade cancer (0.84, range 0.67 to 1.05). [50]
• UK primary care (12,779 men with low testosterone): no increase (hazard ratio 0.97). [51]
• A registry of 999 men: 55 biopsies were done for suspected cancer, and the share that found cancer was nearly the same with testosterone (37.5%) and without (37.0%). [52]

The AUA tells clinicians to inform men "of the absence of evidence linking testosterone therapy to the development of prostate cancer", and the EAU says the literature does not support an increased risk. The Endocrine Society's July 2026 statement adds that long-term safety, including for prostate cancer, "remains unestablished", because the cancer develops slowly and trials may not have followed men long enough. [9], [10], [40]

Does TRT protect against prostate cancer?

No trial shows that. Records studies from Ontario (hazard ratio 0.60 at the highest exposure) and US Medicare (odds ratio 0.72 for cancer that had spread, with injections) found fewer cancers on testosterone. But the Medicare authors warn of "residual confounding", meaning other differences between the groups. In a US insurance database of 3.2 million men, men on testosterone had fewer localized cancers (0.49), but so did men with untreated low testosterone (0.46). That points to low testosterone or testing habits rather than the treatment. [53], [54], [55]

Does TRT make the prostate bigger or urinary symptoms worse?

On average, not in trials, although the evidence for men with severe symptoms is thin.

• TRAVERSE. The change in IPSS did not differ. Severe symptoms (IPSS above 19) at any visit occurred in 7.5% on testosterone and 8.2% on placebo; acute urinary retention in 20 men (0.77%) vs 16 (0.61%); new urinary medicine in 101 (3.89%) vs 87 (3.34%). Procedures for BPH were numerically more common on testosterone, 23 men (0.89%) vs 12 (0.46%) (hazard ratio 1.91, range 0.95 to 3.84), but not statistically clearly so. [1]
• Reviews. Reviews of 14 trials (2,029 men) and 28 trials (3,461 men) found no change in IPSS, and the larger one no change in prostate size. A network review of 21 trials found no worsening by any route, though short-term intramuscular injections enlarged the prostate slightly in one subgroup. [7], [56], [57]
• Who was studied. In a review of 35 trials, 46% excluded men with severe symptoms, and no high-quality evidence supports the common rule against treating them. That missing evidence, not proof of harm, is why the rule persists. [8]
• Prostate size. In 53 older men with BPH on gel, adding dutasteride shrank the prostate by 12% and lowered PSA by 35%, while gel alone grew it by 7.5% and raised PSA by 19%. [58] The Canadian AndroGel monograph lists "enlarged prostate" (11.9%) as the most frequently observed side effect at the recommended dose, with no placebo figure for comparison. [59]
• Small studies suggesting improvement. In an open trial of 52 men with BPH and low testosterone, symptom scores improved within the treated group (15.7 to 12.5), without blinding. [60]

Is TRT safe for the prostate?

For men without prostate cancer, trials lasting about 2 to 3 years have not shown more prostate cancer or worse mild-to-moderate urinary symptoms. PSA does rise a little, which leads to more referrals and some biopsies, and nobody knows the answer over 10 or 20 years. [1], [40]

What do product labels say today?

Checked September 2026. Labels differ by country and are changing.

• United States. Testosterone is contraindicated in known or suspected prostate cancer, and prescribers should check for prostate cancer before and during treatment. Men with BPH are at increased risk of worse symptoms, and older vial labels add that they "may develop acute urethral obstruction". [61], [24]
• United Kingdom. Testogel, other gels and Sustanon 250 contraindicate known or suspected prostate cancer; Nebido and enanthate injections say androgen-dependent prostate cancer. Nebido warns that androgens "may accelerate the progression of sub-clinical prostatic cancer and benign prostatic hyperplasia". [25], [62], [63], [64], [65], [66]
• Canada. Monographs contraindicate known or suspected prostate cancer. Health Canada started a safety review in May 2026, prompted by the FDA, reassessing the prostate cancer risk of testosterone products; no label change has been announced. [59], [67], [68]
• Australia. Testogel and Reandron use the same contraindication; the Testogel document adds that data on prostate cancer risk "are inconclusive". [69], [70]

What did the FDA ask to change in 2026?

On June 18, 2026, the US Department of Health and Human Services announced that the FDA was asking makers to change testosterone labels in three ways. Testosterone would be contraindicated "only in men with metastatic prostate cancer". Labels would say trial data "do not demonstrate worsening symptoms in men with mild to moderate benign prostatic hyperplasia, although evidence remains limited for men with severe symptoms". And they would drop the statement that safety in age-related low testosterone is not established. The FDA's testosterone page confirms the requests. [11], [71]

These are requests, not label changes. As of September 2026, US labels, including Depo-Testosterone (revised August 2026) and a generic cypionate label effective September 9, 2026, still say "known or suspected". [12], [61]

What did TRAVERSE show about heart safety overall?

Heart attack, stroke or cardiovascular death occurred in 182 of 2,596 men on testosterone gel and 190 of 2,602 on placebo. That is 7.0% of men on testosterone gel and 7.3% on placebo (hazard ratio 0.96), meeting the trial's safety goal. Atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and pulmonary embolism (0.9% vs 0.5%) were more common on testosterone. So were fractures, in 91 of 2,601 men (3.50%) vs 64 of 2,603 (2.46%). The limits above apply: gel only, 21.7 months of use on average, about 61% stopped their study gel early, and the men were already at high heart risk. [6], [44], [72] The TRT and heart health guide covers the trial in full.

Who should be especially cautious?

• Men with a raised PSA or a prostate lump not yet checked: above 4 ng/mL, or 3 at high risk, most guidelines want a urologist's evaluation first. [2], [3], [4]
• Men at higher risk of prostate cancer: a father or brother with it, African American or African descent, or a BRCA2 gene change. Several guidelines start screening earlier for them. [2], [17], [13]
• Men with severe urinary symptoms (IPSS above 19): a reason not to start for the Endocrine Society, the VA and the BSSM, a relative contraindication for the EAU and a precaution in Australia. [2], [4], [3], [10], [73]
• Men with prostate cancer now or in the past. See testosterone after prostate cancer.
• Men taking finasteride or dutasteride, whose PSA reads about half its true level. [14], [29]
• Drug-tested athletes, since testosterone is banned in sport. [16]
• Under-18s. Testosterone for teenagers belongs only in specialist care.
• Women. This guide is written for men; see testosterone therapy for women.

Which medicines change PSA or the prostate on TRT?

• Finasteride and dutasteride (5-alpha reductase inhibitors), used for BPH and, at a lower finasteride dose, hair loss. At BPH doses they cut PSA by about 50%; finasteride 1 mg lowered average PSA from 0.7 to 0.5 ng/mL in men aged 18 to 41. Their labels say any confirmed rise from the lowest PSA reached on the medicine should be checked, even if the result still looks normal. [14], [29], [74]
• Their sexual side effects. On the US labels, dutasteride caused impotence in 4.7% vs 1.7% on placebo in the first 6 months, and finasteride 1 mg lower libido in 1.8% vs 1.3%. [29], [74]
• With testosterone. In a 12-month trial of 23 men on testosterone, PSA fell 0.46 ng/mL with dutasteride and rose 0.21 without it, a trend that was not statistically clear. [75]
• Prostate supplements such as saw palmetto and pygeum were not reviewed here; see the saw palmetto and pygeum guides.

Tell whoever orders your PSA test about everything you take, including hair-loss treatments and supplements. Checked September 2026.

Is testosterone legal, and is it allowed in sport?

Checked September 2026. Rules differ by country and change often.

• United States. Testosterone and its esters are Schedule III controlled substances, prescription only. No proposal to change that has been published. [15]
• United Kingdom. Testosterone is a Class C controlled drug, in Schedule 4 Part II of the Misuse of Drugs Regulations. [76]
• Canada. Testosterone is a Schedule IV controlled substance. [77]
• Australia. Testosterone is a Schedule 4 prescription-only medicine. [78]
• Sport. The World Anti-Doping Agency (WADA) prohibits testosterone at all times, and its 2027 list, published in September 2026, keeps the ban. [16], [79]

What do guidelines say to do about a PSA rise or urinary symptoms?

Repeat a surprising PSA result, then refer to a urologist if a confirmed rise crosses the guideline's line; pausing or biopsy follows ordinary prostate cancer rules. This describes the choices clinicians weigh, not a personal plan. [2], [10], [20]

[2], [28], [17], [3], [4], [5], [10], [20], [73]

Should a raised PSA be repeated first?

Yes, under every guideline that addresses it. The Endocrine Society tells clinicians to confirm a rise by repeating the test. The AUA's early-detection guideline notes that a newly raised PSA returns to normal in 25% to 40% of men on retesting. The EAU advises a second test after four weeks, in the same lab with the same test, for results of 3 to 10 ng/mL. PSA can vary by about 15% between tests in the same man. [2], [28], [17] See what to avoid before a PSA test.

Will TRT be stopped if PSA goes above 4?

Not automatically. The CUA says a pause may be advised while a raised PSA is investigated, but a significant rise "should not be attributed to the use of testosterone alone" and needs investigating either way. The EAU leaves the decision to local prostate cancer guidelines. For men with a past prostate cancer, the AUA notes that stopping testosterone may itself lower PSA. [20], [10], [9]

Can you start TRT with an enlarged prostate or urinary symptoms?

With mild to moderate symptoms, most guidelines do not rule it out. With severe symptoms (IPSS above 19), the Endocrine Society, the VA and the BSSM list them as a reason not to start, the EAU as a relative contraindication, and the Australian statement as a precaution. TRAVERSE excluded these men. US labels warn that BPH may worsen, and the FDA has requested softer wording for mild to moderate BPH (requested, not in labels; checked September 2026). Most bodies land on this line because such men were left out of trials, not because harm was shown. [2], [4], [3], [10], [73], [1], [24], [11], [8]

Can you take testosterone after prostate cancer?

Most guidelines rule it out in cancer that has spread. The AUA instead says it should ideally be given there only in research, and the ICSM also rules it out when PSA has come back after treatment. After low-risk cancer has been treated, the AUA, the EAU and the BSSM allow a carefully monitored trial, on short-term evidence.

[9], [10], [80], [21], [20], [3], [2], [4], [73], [61], [11]

The two EAU documents disagree: one limits testosterone to low-risk cancer after surgery and a year of undetectable PSA; the other sees no contraindication wherever hormone-blocking treatment is not the treatment of choice. [10], [80]

• The only randomized trial (2026). 136 men treated with surgery for low-grade cancer (Gleason 6 or 3+4), with undetectable PSA for at least 2 years, got testosterone cypionate 100 mg a week or placebo for 12 weeks. No man had a PSA recurrence; sexual activity and desire improved, erections did not. It was too short and small to judge long-term safety, and does not apply to high-grade cancer or men treated with radiation or hormone therapy. [81], [82]
• The largest records study. Among 69,984 US veterans treated with surgery or radiation, 1,012 later received testosterone (median follow-up 6.95 years); it was not linked with more recurrence (hazard ratio 1.07) or death. [83]
• Pooled studies. Recurrence was about 1% in a review of 21 studies (0% after surgery, 2% after radiation or other non-surgical treatment) and 3.5% in a 2026 review of 7 studies after surgery (398 men). A review of 109 men with high-risk cancer found no recurrences but called the evidence very low quality and testosterone "investigational" in this group. [84], [85], [86]
• After radiation. Of 98 men, 6 (6.1%) had a recurrence over a median of 40.8 months, with no comparison group. [87]

What about men on active surveillance?

Active surveillance means watching a low-risk cancer with regular tests instead of treating it straight away. The EAU advises telling these men, and men treated with radiation or other non-surgical cures, that safety data on testosterone are unclear. [10] The data are observational and small. In US Medicare, 167 men on surveillance who got testosterone moved on to treatment less often than 6,658 who did not (hazard ratio 0.66), and none died of prostate cancer, against 39 (0.6%). In a cohort of 3,324 men, the 79 on testosterone progressed at the same rate (hazard ratio 0.99). A 2026 review of 7 studies (295 men on testosterone) found no spread and no cancer deaths, from low-quality, short studies. It put the lower treatment rate in the Medicare study down most plausibly to which men were chosen for testosterone. [88], [89], [90]

ClinicalTrials.gov lists a non-randomized study recruiting up to 600 men on surveillance, with or without testosterone, for up to 5 years, and a planned single-group study of 35 men. We found no randomized trial recruiting such men. Checked September 2026. [91], [92]

How do sex, cycling and infections affect a PSA test?

What should you avoid before a PSA test?

The NHS asks men not to ejaculate, have anal sex, cycle or exercise hard enough to get out of breath for 48 hours before a PSA test. It also asks them to wait 4 to 6 weeks after a urine infection has cleared. [13] The studies behind those rules:

• Ejaculation raised PSA in 87% of 64 men, and 97% were back to baseline by 48 hours; in a smaller study, 40% were still above baseline at 24 hours. [93], [94]
• Cycling. A long ride raised PSA by 9.5% (0.23 ng/mL) in 129 men aged 50 or older, but a review of 8 studies found no significant change. The NHS rule is the cautious choice. [95], [96]
• Rectal exams and catheters did not meaningfully raise PSA (2,736 and 70 men). [97], [98], [17]
• Urinary retention and biopsy. Retention roughly doubled PSA for up to 2 weeks, and the EAU advises waiting at least a month after a biopsy. [99], [17]

The fairest comparison is a repeat test under the same conditions as the last one: the same lab and test, a similar time of day, and none of these triggers. [17]

Do you need a rectal exam?

It depends on the guideline. The EAU makes a DRE mandatory at the start and recommends one at least yearly. The Endocrine Society and the EAA pair it with PSA at the start, and the BSSM advises one initial exam, then yearly PSA. The UK Society for Endocrinology does not recommend mandatory prostate screening because a man is on testosterone. [10], [2], [5], [3], [22]

What do people on TRT report about their prostate?

Public forums are full of men looking at a PSA result that went up, or wondering whether testosterone will worsen an enlarged prostate. The threads below are recent public Reddit discussions, read with their replies; they show what people experience, not how often it happens.

What does a PSA rise usually look like?

Usually small. One man in his 40s went from 0.74 before treatment to 1.12 at 8 weeks and 1.28 at 5 months, and his urologist simply rechecked it. Another man's results moved between 0.87 and 1.17 over a year, and a third had 3.3 at 10 weeks, the same as before. [100], [101], [102] Bigger jumps worry people most: a man in his 70s saw 1.4 become 2.6 at 6 weeks, and a man in his 50s saw 2.358 become 3.999 at 3 months. [103], [104]

What happened after a big jump?

Posters often blame something just before the test. One man's 1.5 followed ejaculation the night before, and another's 4.3 on cream came after sex and cycling; his clinic would not refill until a urologist cleared him. [105], [106] A retest does not always fall. A man aged 50 went from 2.2 to 7.1 after several dose increases and weekend workouts on an exercise bike. He was still at 6.28 three days later, so his clinic stopped treatment until a urologist saw him. In the same thread, another man said his 4.5 after an indoor bike workout was normal on a retest two weeks later. [107] A man in his 60s on gel climbed from 2.2 before treatment to 3.1 and then 4.6 over two years, and was referred. [108]

Several men describe stopping testosterone for a few weeks before a PSA test so the number comes down; a result taken during a break is not the on-treatment PSA that guideline triggers compare. [107], [109]

What do men with an enlarged prostate report?

Experiences split. A man with mild BPH on medicine for it was cleared by his urologist and, 8 weeks into a low dose, said his dribbling and night-time urination had almost gone. [110] Others with mild BPH described urgency that became "not so minor" within a month, or pelvic pressure and a weaker stream by week 8. [111], [112] A man in his 40s stopped after about 5 weeks because of new urgency and trouble emptying his bladder. [113] After about 17 years of treatment, one man had a PSA of 6.1, a prostate that grew from 81 to 107 cc over four years and an MRI with no suspicious areas. [114] Some complaints are hard to pin down: one man's stream weakened before each long-acting injection, alongside a known narrowing of the urethra. [115]

What do men report before starting?

A raised PSA changes the path. Clinics declined one man with a PSA of 3.5, and another's PSA of 8 led to a negative biopsy. A third learned his baseline PSA was 7.7 only after two doses, because the clinic had prescribed before his results were back. [116], [117], [118] A man with readings of 5.6 and 5.5 had a clear MRI and, a year later, a PSA of 4.1 and normal testosterone. [119] A man not on testosterone saw PSA fall from 3.6 to 2.4 while losing weight, and another with BPH and a high PSA was cleared by a urologist to start. [120], [121]

What do men report after prostate cancer?

A man in his 60s said his oncologist would allow testosterone with close PSA checks after radiation and hormone therapy, while his family doctor opposed it. A reply from a man in his 70s described PSA low and stable at 0.4 almost 3 years after restarting. Another man in his 70s, treated in 2024, said his PSA had not risen in a year back on testosterone. [122], [109] These accounts cannot show how safe this is.

How do clinicians respond to prostate worries?

Often cautiously. Two men describe prescribers refusing a dose increase over prostate risk, in one case a grandfather's cancer, and both considered or booked another prescriber. [123], [124] One man said he was afraid to mention urinary symptoms in case treatment was stopped; he had also changed his injection schedule and started a hair-loss spray. [125] Men who took finasteride or dutasteride describe sexual side effects such as losing morning erections; in one case they faded weeks to months after stopping. [126], [127]

How can you judge a PSA story?

Ask: What was PSA before treatment? Was the test repeated in the same lab? Did ejaculation, cycling, an infection or a procedure come just before? Was he on finasteride, dutasteride or a break? What did the next test show?

These selected discussions show what people experience and the questions research has not answered. They are not a survey of all men on TRT, a success rate or a substitute for the studies above.

What should you track?

PSA before starting, at 3–12 months, then on your guideline's schedule, plus any change in urinary symptoms. Use this to prepare questions for your prescriber; it is not a personal testing plan. [2], [4], [3]

[2], [4], [3], [25], [10], [14], [13], [32]

A single PSA result is one point on a line; a trend of results drawn under similar conditions says more than any one number. The TRT blood work guide covers the full lab schedule, and the hematocrit guide the other main safety test. [17], [28]

Common questions about TRT and the prostate

Does TRT cause prostate cancer?

Trials have not shown that it does. In TRAVERSE, prostate cancer occurred in 12 men on testosterone and 11 on placebo, out of about 2,600 in each group, and a 2026 review of 41 trials found no clear change. The trials lasted a few years and left out higher-risk men, so long-term safety is not established. [1], [39], [40] See the research.

Is it normal for PSA to go up on TRT?

A small rise is common: 0.15 ng/mL above placebo at 12 months in TRAVERSE, most in older men and those who start very low. A rise that crosses a guideline trigger still needs checking. [1], [32] See why PSA rises.

How much can PSA rise on TRT before it's a problem?

Most guidelines that give a number refer a man to a urologist after a rise of more than 1.4 ng/mL in the first year, or a PSA above 4 ng/mL, usually after a repeat test. The BSSM applies the 1.4 ng/mL rule to any year and also flags more than 0.4 ng/mL a year over 2 years. [2], [3], [4], [5] See the key numbers.

Can you take TRT with BPH?

Often, with mild to moderate symptoms: trials found no worsening on average. Men with severe symptoms (IPSS above 19) were mostly left out, and most guidelines advise caution for them. US labels still warn about BPH; softer wording is requested, not yet in labels (checked September 2026). [1], [8], [11] See urinary symptoms.

Can you take testosterone after prostate cancer?

Sometimes, under specialist care. Most guidelines rule it out in cancer that has spread. The AUA and the EAU allow a monitored trial after low-risk cancer removed by surgery, and the BSSM after treated low-risk cancer. The only randomized trial lasted 12 weeks, and US labels still say no. [9], [10], [3], [81], [61] See after prostate cancer.

Does TRT make the prostate bigger?

Not clearly on average: a review of 28 trials found no significant change in size, though one trial of a higher-than-usual dose found growth of 11.4 cm³ in a year. [56], [30] See the research.

Should you stop TRT before a PSA test?

Not unless your prescriber asks. Guideline triggers compare PSA on treatment with the baseline, so a result taken during a break answers a different question. Avoid ejaculation, cycling and hard exercise for 48 hours instead. [2], [13] See before a PSA test.

Glossary

Plain explanations of the medical, lab and research terms used in this guide. Underlined terms in the text link here.

Active surveillance

Watching a low-risk prostate cancer with regular PSA tests, scans and biopsies instead of treating it straight away. Treatment starts if the cancer shows signs of growing.

ADT (androgen deprivation therapy)

Treatment that lowers testosterone, or blocks it, to slow prostate cancer. It is a standard treatment for cancer that has spread or is at high risk.

Biochemical recurrence

A rise in PSA after prostate cancer treatment that suggests the cancer has come back, before any other sign. After surgery, trials often define it as a PSA of 0.2 ng/mL or more.

BPH (benign prostatic hyperplasia)

An enlarged prostate that is not cancer. It can press on the tube that carries urine and cause urinary symptoms.

Cohort study (records study)

A study that follows a group of people, or looks back at their records, without assigning treatments. It can show links but not prove that one thing caused another.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

DHT (dihydrotestosterone)

A stronger hormone made from testosterone by the enzyme 5-alpha reductase. It drives much of the prostate's growth and hair loss on the scalp.

DRE (digital rectal exam)

A quick exam in which a doctor feels the prostate with a gloved finger through the back passage, checking its size and for lumps or hard areas.

5-alpha reductase inhibitor

A medicine, such as finasteride or dutasteride, that blocks the conversion of testosterone to DHT. It shrinks an enlarged prostate and lowers PSA by about half.

Gleason score

A grade given to prostate cancer under the microscope. Gleason 6 is low grade; 3+4 is the lower end of intermediate grade; higher scores mean more aggressive cancer.

Clinical guideline

Recommendations written by a medical society or health system, based on its review of the evidence and expert judgment. Different guidelines can reach different conclusions.

Hazard ratio

A measure comparing how often an event happens over time in two groups. A hazard ratio of 1 means no difference; 0.96 means about 4% lower in the first group.

Intramuscular (IM)

Injected into a muscle. Most testosterone cypionate and enanthate is given this way.

IPSS (International Prostate Symptom Score)

A short questionnaire that scores urinary symptoms such as a weak stream, urgency and getting up at night. TRT guidelines treat a score above 19 as severe.

Product label (prescribing information)

The official document approved by a medicines regulator for a product, describing its approved uses, doses, warnings and monitoring. In the UK it is called the summary of product characteristics.

Lower urinary tract symptoms (LUTS)

Problems passing or storing urine, such as a weak or stop-start stream, urgency, dribbling or getting up at night. BPH is a common cause, but not the only one.

Mendelian randomization

A study method that uses gene variants people are born with as a natural experiment, to test whether a lifelong difference, such as higher testosterone, is linked with a disease.

Meta-analysis and systematic review

A systematic review gathers all studies on a question in a planned way. A meta-analysis combines their results statistically. A network meta-analysis compares several treatments at once, even ones never tested head to head.

Metastatic

Cancer that has spread from where it started to other parts of the body, such as the bones or lymph nodes.

Odds ratio

A measure comparing the odds of an outcome in two groups. An odds ratio of 2 means roughly twice the odds; 1 means no difference.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

PSA (prostate-specific antigen)

A blood test for a protein made by the prostate. It rises slightly on testosterone and is used to decide whether prostate checks are needed. It is reported in ng/mL or µg/L, which are the same number.

PSA velocity

How fast PSA rises over time, usually in ng/mL per year. The BSSM flags a rise of more than 0.4 ng/mL a year over more than 2 years.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. Xyosted is given this way, and some prescribers use this route for other testosterone injections.

TRT (testosterone replacement therapy)

Prescribed testosterone, by injection, gel or other forms, for men with low testosterone.

Acute urinary retention

Suddenly being unable to pass urine, which usually needs a catheter. An enlarged prostate is a common cause.

Urologist

A doctor who specializes in the urinary tract and male reproductive organs, including the prostate.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is prohibited at all times.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: clinical guidelines from ten medical bodies plus prostate cancer screening guidance, product labels from four countries, published clinical trials and studies, and regulatory documents. We also reviewed public online forums where men on TRT describe their own PSA results and urinary symptoms.

The guide cites 127 sources, including 35 original studies in people, 17 clinical guidelines, position statements and screening recommendations, and 28 public community discussions. Each type of source answers a different question. Guidelines and labels show what clinicians are told to do. Trials and studies show what was measured. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources